Titre :
  • The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C.
Auteur : Zeuzem, Stefan ; Buggisch, Peter ; Agarwal, Kosh ; Marcellin, P ; Sereni, Daniel ; Klinker, Hartwig ; Moreno, Christophe ; Zarski, Jean-Pierre ; Horsmans, Y. ; Mo, Hongmei ; Arterburn, Sarah ; Knox, Steven ; Oldach, David ; McHutchison, John G ; Manns, Michael P ; Foster, Graham R
Informations sur la publication : Hepatology, 55, 3, (page 749-758)
Statut de publication : Publié, 2012-03
Sujet CREF : Sciences bio-médicales et agricoles
Mots-clés MeSH : Adult
Antiviral Agents -- therapeutic use
Dose-Response Relationship, Drug
Drug Therapy, Combination
Enzyme Inhibitors -- therapeutic use
Female
Genotype
Hepacivirus -- genetics
Hepatitis C -- blood -- drug therapy
Humans
Interferon-alpha -- therapeutic use
Male
Middle Aged
Peptides, Cyclic -- therapeutic use
Phosphinic Acids -- therapeutic use
Polyethylene Glycols -- therapeutic use
Protease Inhibitors -- therapeutic use
Purines -- therapeutic use
Pyridazines -- therapeutic use
RNA, Viral -- blood
Recombinant Proteins -- therapeutic use
Ribavirin -- therapeutic use
Treatment Outcome
Note : Clinical Trial, Phase II
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
SCOPUS: ar.j
FLWIN
Langue :
  • Anglais
Identificateurs : urn:issn:0270-9139 
info:doi/10.1002/hep.24744
info:pmid/22006408